Keywords: Takeda, Steovess, Osteoporosis, European Commission, EffRx Pharma
Takeda’s Steovess accepted for national approvals in EU
Article | 23 December 2011
Japan’s largest drugmaker Takeda Pharmaceuticals (TYO: 4502) says that the European decentralized procedure (DCP) was positively concluded for Steovess ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
